ProCE Banner Activity

Combination Therapy With Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML

Slideset Download
Conference Coverage
The combination of azacitidine, venetoclax, and magrolimab demonstrated high response rates with a manageable safety profile in venetoclax-naive patients with newly diagnosed or relapsed/refractory AML.

Released: December 21, 2021

Expiration: December 20, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation